XD 14

• CAT Number: I011216
• CAS Number: 1370888-71-3
• Molecular Formula: C20H27N3O5S
• Molecular Weight: 421.51
• Purity: ≥95%
• Synonyms: 4-Acetyl-N-[5-[(diethylamino)sulfonyl]-2-hydroxyphenyl]-3-ethyl-5-methyl-1H-pyrrole-2-carboxamide
• Target: Epigenetic Reader Domain
• Solubility: Soluble to 100 mM in DMSO and to 100 mM in ethanol
• Storage: Store at -20C
• IUPAC Name: 4-acetyl-N-[5-(diethylsulfamoyl)-2-hydroxyphenyl]-3-ethyl-5-methyl-1H-pyrrole-2-carboxamide
• InChI: InChI=1S/C20H27N3O5S/c1-6-15-18(13(5)24)12(4)21-19(15)20(26)22-16-11-14(9-10-17(16)25)29(27,28)23(7-2)8-3/h9-11,21,25H,6-8H2,1-5H3,(H,22,26)
• InChIKey: DPBKLIVPNYGQQG-UHFFFAOYSA-N
• SMILES: CCC1=C(NC(=C1C(=O)C)C)C(=O)NC2=C(C=CC(=C2)S(=O)(=O)N(CC)CC)O

XD 14(CAT: I011216) is a potent and selective inhibitor of BET (bromodomain and extra-terminal) proteins, which play a critical role in regulating gene expression by interacting with acetylated histones. By targeting BET bromodomains, XD 14 disrupts transcriptional processes associated with inflammation, cancer, and other diseases driven by epigenetic dysregulation. This compound is widely used in preclinical research to study the therapeutic potential of BET inhibition in oncology, immunology, and inflammatory diseases. With high specificity and efficacy, XD 14 is a valuable tool for advancing drug discovery and understanding the epigenetic mechanisms underlying various pathological conditions.